Clinical trials Below are current clinical trials.165 studies in Hematology (open studies only). Filter this list of studies by location, status and more. A Safety Study of SEA-TGT in Patients With Advanced Cancer Rochester, Minn. This trial will look at a drug called SGN-TGT to find out whether it is safe for patients with solid tumors and lymphomas. It will study SGN-TGT to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether SGN-TGT works to treat solid tumors and lymphomas. The study will have three groups or "parts." Part A of the study will find out how much SGN-TGT should be given to patients. Part B will use the dose found in Part A to find out how safe SGN-TGT is and if it works to treat solid tumors and lymphomas. Part C will study how well SGN-TGT with a PD-(L)1 inhibitor works to treat solid tumors and lymphomas. PD-(L)1 inhibitors are drugs that can be used to treat these types of cancer. A Study to Evaluate Minimal Residual Disease in Chronic Lymphocytic Leukemia Rochester, Minn. The purpose of this study is to compare whether minimal residual disease (MRD) flow cytometric assay is not affected by different anticoagulants. Hematology Electronic Consultations (e-Consults) the Mayo Clinic Experience Jacksonville, Fla. The purpose of this study is to evaluate hematology e-consults to determine their specific use, time to completion, advantages and disadvantages, perceptions from primary care physicians and specialists and economic impact. Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma Jacksonville, Fla. The purpose of this study is to determine the safety and effectiveness of bb2121 (Ide-Cel) combinations in subjects with relapsed/refractory multiple myeloma. It also aims to evaluate different agents and their doses/schedules to improve clinical effectiveness in combination with bb2121. A Study to Evaluate Lenalidomide and Dexamethasone, with or without Daratumumab, in Treating High-Risk Smoldering Myeloma Patients Rochester, Minn., Eau Claire, Wis., Albert Lea, Minn. The purpose of this study is to show how well lenalidomide and dexamethasone work with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and dexamethasone with daratumumab may work better in treating patients with smoldering myeloma. A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Relapsed or Refractory Hematologic Malignancies Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla. This is a multi-center, open-label trial of orally administered CA-4948 monotherapy in adult patients with Relapsed or Refractory NHL. The trial will be conducted in 2 parts: an initial Dose Escalation Phase (Part A) of CA-4948 in patients with Relapsed or Refractory Non-Hodgkin Lymphoma, (RR NHL) and a Dose Expansion Phase (Part B) of CA-4948 in patients with RR NHL with and without myeloid differentiation primary response 88 (MYD88) mutations. During Part B, patients will be enrolled regardless of MYD88 mutation status. A Study to Assess Point of Care Platelet Function Rochester, Minn. The purpose of this study is to compare Placor outputs between two groups (Group 1, healthy donors and Group 2, not acutely ill donors reporting daily clopidogrel use). 20 heathy donors and 20 patients maintained on clopidogrel therapy (half on clopidogrel alone and half on both aspirin and clopidogrel therapy) will be enrolled. Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia Rochester, Minn. This phase Ib/II clinical trial studies the side effects and best dose of venetoclax and how well it works when given together with vincristine liposomal in treating patients with T-cell or B-cell acute lymphoblastic leukemia that has come back or does not respond to treatment. Venetoclax may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as vincristine liposomal, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax together with vincristine liposomal may work better in treating patients with acute lymphoblastic leukemia. Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma Rochester, Minn., Scottsdale/Phoenix, Ariz. This phase I/II trial studies the side effects and best dose of romidepsin and lenalidomide when combined with rituximab and to see how well this combination works in treating patients with B-cell non-Hodgkin lymphoma that has returned (recurrent) or did not respond to treatment (refractory). Monoclonal antibodies, such as rituximab, may block cancer growth in different ways by targeting certain cells. Romidepsin and lenalidomide may stop the growth of cancer cells by blocking enzymes needed for cell growth. Giving rituximab together with romidepsin and lenalidomide may be a better treatment for B-cell non-Hodgkin lymphoma. A Study to Evaluate CTX110 in Subjects with Relapsed or Refractory B-Cell Malignancies Jacksonville, Fla. The purpose of this study is to evaluate the safety and effectiveness CTX110 in subjects with relapsed or refractory B cell malignancies. Pagination Clinical studies PrevPrevious Page Go to page 33 Go to page 44 Go to page 55 Go to page 66 Go to page 77 NextNext Page Request an Appointment at Mayo Clinic Locations, travel & lodgingResearch Jan. 07, 2022 Share on: FacebookTwitter HematologyDepartment homeSectionsRequest an appointmentOverviewTests & proceduresConditions treatedDoctorsSpecialty groupsExpertise & rankingsLocations, travel & lodgingClinical trialsResearchThe Mayo Clinic experience & patient storiesCosts & insuranceNews from Mayo ClinicReferrals Research: It's All About Patients SectionsRequest an appointmentOverviewTests & proceduresConditions treatedDoctorsSpecialty groupsExpertise & rankingsLocations, travel & lodgingClinical trialsResearchThe Mayo Clinic experience & patient storiesCosts & insuranceNews from Mayo ClinicReferrals ORG-20180185 Departments & Centers Medical Departments & Centers Hematology